BRAF(V600E) and microenvironment in thyroid cancer: a functional link to drive cancer progression.
about
Signaling Pathways in Thyroid Cancer and Their Therapeutic ImplicationsTERT promoter mutations in thyroid cancerPeptide Hydrogels - Versatile Matrices for 3D Cell Culture in Cancer MedicinePersonalized therapy in patients with anaplastic thyroid cancer: targeting genetic and epigenetic alterationsBRAF activates and physically interacts with PAK to regulate cell motilityIntegrated genomic characterization of papillary thyroid carcinomaOxidative stress: a new risk factor for thyroid cancerCorrelative Studies in Clinical Trials: A Position Statement From the International Thyroid Oncology GroupIdentification and synthesis of N-(thiophen-2-yl) benzamide derivatives as BRAF(V600E) inhibitors.TERT promoter mutations and their association with BRAF V600E mutation and aggressive clinicopathological characteristics of thyroid cancer.Molecular pathogenesis and mechanisms of thyroid cancerSEREX: a promising approach for identification of thyroid cancer serological biomarkers.A missense polymorphism (rs11895564, Ala380Thr) of integrin alpha 6 is associated with the development and progression of papillary thyroid carcinoma in Korean populationLate intervention with anti-BRAF(V600E) therapy induces tumor regression in an orthotopic mouse model of human anaplastic thyroid cancer.Epigenetics modifications and therapeutic prospects in human thyroid cancer.Comprehensive Analysis of the Transcriptional and Mutational Landscape of Follicular and Papillary Thyroid Cancers.Identification of insertions in PTEN and TP53 in anaplastic thyroid carcinoma with angiogenic brain metastasis.BRAF mutation in papillary thyroid carcinomaDeciphering the Key Features of Malignant Tumor Microenvironment for Anti-cancer TherapyBRAF V600E status adds incremental value to current risk classification systems in predicting papillary thyroid carcinoma recurrence.Recent insights into the cell biology of thyroid angiofollicular units.B-Raf mutation and papillary thyroid carcinoma patients.Combining BRAF inhibitor and anti PD-L1 antibody dramatically improves tumor regression and anti tumor immunity in an immunocompetent murine model of anaplastic thyroid cancerBRAF and TERT promoter mutations in the aggressiveness of papillary thyroid carcinoma: a study of 653 patientsAssociation between BRAF V600E mutation and mortality in patients with papillary thyroid cancer.Thrombospondin-1 Silencing Down-Regulates Integrin Expression Levels in Human Anaplastic Thyroid Cancer Cells with BRAF(V600E): New Insights in the Host Tissue Adaptation and Homeostasis of Tumor MicroenvironmentPigment epithelium-derived factor has a role in the progression of papillary thyroid carcinoma by affecting the HIF1α-VEGF signaling pathway.The next generation of orthotopic thyroid cancer models: immunocompetent orthotopic mouse models of BRAF V600E-positive papillary and anaplastic thyroid carcinomaCollagen remodeling and peripheral immune cell recruitment characterizes the cutaneous Langerhans cell histiocytosis microenvironment.Cytotoxic and genotoxic effects of 131 I and 60 Co in follicular thyroid cancer cell (WRO) with and without recombinant human thyroid-stimulating hormone treatment.Molecular Aberrance in Papillary Thyroid Microcarcinoma Bearing High Aggressiveness: Identifying a "Tibetan Mastiff Dog" From Puppies.The sonic hedgehog signaling pathway stimulates anaplastic thyroid cancer cell motility and invasiveness by activating Akt and c-Met.DARPP-32 is required for MAPK/ERK signaling in thyroid cells.Role of gene expression profiling in defining indeterminate thyroid nodules in addition to BRAF analysis.Effects of radioiodine administration on serum concentrations of matrix metalloproteinases, adiponectin and thrombospondin-1.Clinical outcome, role of BRAF(V600E), and molecular pathways in papillary thyroid microcarcinoma: is it an indolent cancer or an early stage of papillary thyroid cancer?BRAF mutation positive papillary thyroid carcinoma is less advanced when Hashimoto's thyroiditis lymphocytic infiltration is present.Tumor-suppressive function of UNC5D in papillary thyroid cancer.Progress towards personalized medicine for ameloblastoma.The association of the BRAF(V600E) mutation with prognostic factors and poor clinical outcome in papillary thyroid cancer: a meta-analysis.
P2860
Q26764899-34C4D690-54E1-42D1-A5F0-2CB000C3C508Q26770808-9ED3FE7A-6478-464B-9B32-9BC5B5390D82Q26860533-EF16C014-4FFC-49F3-9F66-EBA8B5E4A094Q27027491-CDECE1F6-35F5-4CF2-9FB2-194C20A87265Q28248127-646B503B-A950-48B0-8882-212DF7C66563Q28251986-7D89207E-0AFE-4A1E-9480-C231234DC501Q28388902-E0345B54-8473-41BC-8BB6-B8AA8C5C45C3Q33587905-BBE02459-B86C-4B74-9E67-98B4E209EB91Q33632493-157687FB-0E3E-4FC5-A8E6-82F12A7AC59DQ33682388-CE3843B7-910F-4F71-8530-302B6DA87629Q34329018-77B46D4A-1B93-4D2F-A6BC-306C9D590C2FQ34566729-6A9A14C3-52E9-4BF9-8228-07408D15C23FQ35587579-5D93F7C2-9016-4AFC-913E-1D8DDB2DD38EQ35744562-245C312D-3322-4AA0-8459-A87E4294CEEBQ35971504-1CFD46DF-4087-4613-A892-6660883F3A7BQ36096044-525E6E1F-9F2A-4301-B3C1-C88FDFBF4CDFQ36171837-20AA578B-2A2E-4632-9354-C92803F5B3A6Q36238518-1394022B-2AAC-47BB-8502-20C4CD97C03BQ36284940-648CFE59-4A23-448D-A0FB-CD65F05083DEQ36413759-855B006F-6C04-4E86-8756-78BB5933171CQ36724051-E3330B86-34F1-4B30-9DF4-D886CE59AB12Q36741221-2722E393-61B2-4EF9-BE25-2CC22FCEEB15Q37086237-D5B1B9CB-2F52-4569-8CBC-B34EB0BEB3BAQ37109755-A3606C03-6AB6-48F5-8F76-E43F8E8E39E0Q37216703-31038CB9-4B88-4A19-A7D2-FA2A7B48B6D4Q37353828-13259EE1-3EF0-4897-912B-87383C9FDCF2Q37582221-AF7CF98F-8C6C-415D-9170-B22AD6A9F8A5Q37712700-081BA69E-4536-4755-9A96-7098DEB9E622Q38392633-0BB6085A-9B87-40BC-B1F2-78202797B752Q38701744-207B69AB-B2E0-458D-B8DD-70F89AA1D578Q38721735-C85E3712-3A61-4755-BD46-881D5521CB3AQ38795464-AFAE33CC-AA75-4F16-A1CE-9E07201BB9B0Q39402299-526AD643-DECA-4C55-B3F4-1E2EE11454BAQ40125465-673B52B4-EFAB-4F4A-A248-93212DECD527Q41820261-F60B4C93-E5AB-433C-AEFB-71A295E8D825Q42174969-C51A60CD-2C56-4FC6-9B33-EFD7A0143A62Q46527691-D71E9174-6711-4D97-AEA6-D79C0DA3F625Q47135233-3C1480BD-438C-4929-AB2D-5FAC45DDEB05Q54358697-A0CEA6D1-F4FD-4A3D-8C91-A62A7F840809Q54564143-1D86B104-BA87-4613-A07B-B5ED39FBA40C
P2860
BRAF(V600E) and microenvironment in thyroid cancer: a functional link to drive cancer progression.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 29 March 2011
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
BRAF(V600E) and microenvironme ...... k to drive cancer progression.
@en
type
label
BRAF(V600E) and microenvironme ...... k to drive cancer progression.
@en
prefLabel
BRAF(V600E) and microenvironme ...... k to drive cancer progression.
@en
P2093
P2860
P1433
P1476
BRAF(V600E) and microenvironme ...... k to drive cancer progression.
@en
P2093
Carmelo Nucera
Jack Lawler
Sareh Parangi
P2860
P304
P356
10.1158/0008-5472.CAN-10-3844
P407
P577
2011-03-29T00:00:00Z